Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The pharmaceutical industry has faced significant changes in recent years, primarily influenced by regulatory standards, market competition, and the need to accelerate drug development. Model-informed drug development (MIDD) leverages quantitative computational models to facilitate decision-making processes. This approach sheds light on the complex interplay between the influence of a drug’s performance and the resulting clinical outcomes. This comprehensive review aims to explain the mechanisms that control the dissolution and/or release of drugs and their subsequent permeation through biological membranes. Furthermore, the importance of simulating these processes through a variety of in silico models is emphasized. Advanced compartmental absorption models provide an analytical framework to understand the kinetics of transit, dissolution, and absorption associated with orally administered drugs. In contrast, for topical and transdermal drug delivery systems, the prediction of drug per...meation is predominantly based on quantitative structure–permeation relationships and molecular dynamics simulations. This review describes a variety of modeling strategies, ranging from mechanistic to empirical equations, and highlights the growing importance of state-of-the-art tools such as artificial intelligence, as well as advanced imaging and spectroscopic techniques.
Кључне речи:
oral absorption / drug release / drug dissolution / drug permeation / model-informed drug development / modeling / percutaneous permeation / release mechanism / solubilityИзвор:
Pharmaceuticals, 2024, 17, 2Издавач:
- MDPI
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200161 (Универзитет у Београду, Фармацеутски факултет) (RS-MESTD-inst-2020-200161)
DOI: 10.3390/ph17020177
ISSN: 142-48247
PubMed: 38399392
WoS: 001172258100001
Scopus: 2-s2.0-85187199266
Институција/група
PharmacyTY - JOUR AU - Đuriš, Jelena AU - Cvijić, Sandra AU - Đekić, Ljiljana PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5566 AB - The pharmaceutical industry has faced significant changes in recent years, primarily influenced by regulatory standards, market competition, and the need to accelerate drug development. Model-informed drug development (MIDD) leverages quantitative computational models to facilitate decision-making processes. This approach sheds light on the complex interplay between the influence of a drug’s performance and the resulting clinical outcomes. This comprehensive review aims to explain the mechanisms that control the dissolution and/or release of drugs and their subsequent permeation through biological membranes. Furthermore, the importance of simulating these processes through a variety of in silico models is emphasized. Advanced compartmental absorption models provide an analytical framework to understand the kinetics of transit, dissolution, and absorption associated with orally administered drugs. In contrast, for topical and transdermal drug delivery systems, the prediction of drug permeation is predominantly based on quantitative structure–permeation relationships and molecular dynamics simulations. This review describes a variety of modeling strategies, ranging from mechanistic to empirical equations, and highlights the growing importance of state-of-the-art tools such as artificial intelligence, as well as advanced imaging and spectroscopic techniques. PB - MDPI T2 - Pharmaceuticals T1 - Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration VL - 17 IS - 2 DO - 10.3390/ph17020177 ER -
@article{ author = "Đuriš, Jelena and Cvijić, Sandra and Đekić, Ljiljana", year = "2024", abstract = "The pharmaceutical industry has faced significant changes in recent years, primarily influenced by regulatory standards, market competition, and the need to accelerate drug development. Model-informed drug development (MIDD) leverages quantitative computational models to facilitate decision-making processes. This approach sheds light on the complex interplay between the influence of a drug’s performance and the resulting clinical outcomes. This comprehensive review aims to explain the mechanisms that control the dissolution and/or release of drugs and their subsequent permeation through biological membranes. Furthermore, the importance of simulating these processes through a variety of in silico models is emphasized. Advanced compartmental absorption models provide an analytical framework to understand the kinetics of transit, dissolution, and absorption associated with orally administered drugs. In contrast, for topical and transdermal drug delivery systems, the prediction of drug permeation is predominantly based on quantitative structure–permeation relationships and molecular dynamics simulations. This review describes a variety of modeling strategies, ranging from mechanistic to empirical equations, and highlights the growing importance of state-of-the-art tools such as artificial intelligence, as well as advanced imaging and spectroscopic techniques.", publisher = "MDPI", journal = "Pharmaceuticals", title = "Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration", volume = "17", number = "2", doi = "10.3390/ph17020177" }
Đuriš, J., Cvijić, S.,& Đekić, L.. (2024). Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration. in Pharmaceuticals MDPI., 17(2). https://doi.org/10.3390/ph17020177
Đuriš J, Cvijić S, Đekić L. Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration. in Pharmaceuticals. 2024;17(2). doi:10.3390/ph17020177 .
Đuriš, Jelena, Cvijić, Sandra, Đekić, Ljiljana, "Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration" in Pharmaceuticals, 17, no. 2 (2024), https://doi.org/10.3390/ph17020177 . .